3654 results for «600»
3654 results
PCI for complex calcific coronary artery disease - LIVE Case
22 May 2025 – From EuroPCR 2025
An 87-year-old female patient, at high bleeding risk and with preserved LV function, presented 2 months ago with an inferior STEMI and multivessel disease. She initially underwent RCA PCI followed by staged LCx PCI. She was now referred for PCI of a long, heavily calcified lesion...
TAVI in bicuspid: all you need to know
22 May 2025 – From EuroPCR 2025
Understand the unique anatomical and clinical challenges of transcatheter aortic valve implantation (TAVI) in bicuspid aortic valves. This session covers bicuspid valve epidemiology, indications for surgery and TAVI, and detailed discussion on sizing and deployment fundamentals specific to bicuspid anatomy to optimize procedural success.
Challenging session in calcified lesions
22 May 2025 – From EuroPCR 2025
Engage with a challenging session focused on complex calcified lesion interventions. Topics include innovative triple burr techniques, OCT insights into resistant lesions, volume reduction strategies, eccentric calcium management, and IVUS-guided left main calcified lesion treatment, highlighting practical approaches to difficult cases.
The role of DCB in non-left main true bifurcations
22 May 2025 – From EuroPCR 2025
This session offers a detailed exploration of drug-coated balloon (DCB) use in non-left main true bifurcation lesions. Learn to define suitable lesion characteristics for provisional stenting, understand stepwise procedural strategies minimizing implanted material, and appreciate the role of intravascular imaging in assessing bifurcation complexity and optimizing...
Leaflet modification to prevent coronary obstruction during TAVI
22 May 2025 – From EuroPCR 2025
This session addresses advanced leaflet modification techniques to prevent coronary obstruction during TAVI. Learn from detailed cases involving valve-in-valve interventions, treatment of failed stentless valves, homograft management, and dedicated devices for leaflet modification prior to valve-in-valve and valve-in-valve-in-valve procedures.
TAVI: high coronary risk
16 Nov 2025 – From PCR London Valves 2025
This session addresses the complexities and innovative approaches to managing high coronary risk during TAVI procedures. It features advanced techniques such as the double chimney-stent method, valve-in-valve strategies to prevent coronary obstruction, and challenging cases involving TAVI-in-TAVI. These insights provide practical guidance for interventionalists navigating high-risk...
CTO PCI in images and case examples: what is new in 2026?
07 Jul 2026
Register for free to this webinar on Monday 31 August at 6:00pm with K. Mashayekhi, M. Ayoub and C. Ungureanu and learn to review the recent evidence on expected outcomes after CTO PCI, and much more!
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)
27 Oct 2023
Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...
Author
The greatest advance in the next 40 years would be to remove the need for angioplasty
17 May 2017
Spencer B. King performed some of the first coronary angioplasty procedures in the USA—having recently received a thank-you from the first patient that he treated. He tells The Daily Wire that the steerable guidewire, rather than the stent, was the greatest advance in angioplasty and that...
Authors :
ALL-RISE: A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide PCI
28 Mar 2026
Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.
Author
COVID-19 vaccines: Burning questions from the community and real-world applicability
13 Jan 2021
View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.
A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina - ORBITA-CTO trial
03 Apr 2026
Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...
Author
Author
Author
From PROTECT-AF to CHAMPION-AF: Where do we stand today?
01 Jul 2026
In this article, Jens Erik Nielsen-Kudsk reviews the evolution of left atrial appendage closure, from early trials such as PROTECT‑AF to recent evidence including CHAMPION‑AF, and discusses its expanding role in stroke prevention for atrial fibrillation.
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)